MedTrace Logo

Changes in Pituitary Iron and Volume With Deferasirox

NCT01376622 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2023-10-31

No results posted yet for this study

Summary

Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.

Conditions

  • Iron Overload

Sponsors & Collaborators

Principal Investigators

  • John C Wood, MD, PhD · Children's Hospital Los Angeles

Eligibility

Min Age
2 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-07-01
Completion
2011-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376622 on ClinicalTrials.gov